Top Five Pharmaceutical Company Sees Increase in Patient Retention with ClinCard

Poor patient retention can have countless detrimental effects on the performance of a clinical trial and a sponsor’s ability to bring new therapies to market.

The consequences of poor retention include, but are certainly not limited to:

  • Subjects not receiving full course of therapy and follow up
  • Delays in clinical trial timelines, product approval
  • Higher costs to complete the clinical trial

Patient retention cannot be an afterthought or a “one size fits all” solution to a clinical trial. There needs to be a thoughtful strategy, that engages all of the stakeholders in the study, formulated at very early stages of trial planning to ensure patients are engaged from beginning to end.

Subject reimbursement is vital to ensuring patients remain involved. And how a patient is reimbursed is equally as important to the fact that they are reimbursed at all. By automating this reimbursement process, sponsors can provide a quick and efficient way for sites to distribute patient stipends.

That is why one of the top five pharmaceutical companies in the world chose the ClinCard Solution to improve patient retention and site performance. The solution brought a series of advantages to the study, including a tangible return on patient retention. The solution automated site visit reimbursements, eliminated manual payments, and reduced administrative burden on site coordinators. It also provided an automated, convenient mechanism to remain in constant communication with the study participants – sending reminders on appointments, notices about payments and balances on the patients’ ClinCards. Patients also gained a secure way to receive immediate reimbursement that could be used to access cash and/or make purchases anywhere that accepts debit cards.

The sponsor implemented a pilot of the ClinCard solution in an effort to gauge the impact that automated reimbursement could have on patient retention, by minimizing financial hurdles that may impact a patient’s involvement and also improving patient engagement via the automated patient messaging features of the solution.

In the four studies that the sponsor completed in the pilot program, which included three adult and one pediatric trial, the sponsor saw a patient retention increase by nearly 10%.

The benefits associated with using the ClinCard helped support the sponsor’s effort in maintaining a positive relationship with patients and their site partners for their studies. The sponsor saw the ClinCard solution as a great way to provide sites with the resources they need to connect with the patients and ensure ongoing participation.

Rick Ward
Written by Rick Ward

Vice President, Business Development